Amaç: Diyabetik makula ödeminde bilateral eş zamanlı veya unilateral intravitreal ranibizumab (IVR tedavisinin erken dönem anatomik ve görsel sonuçlarını karşılaştırmaktır. Gereç ve Yöntemler: Çalışmaya yeni tanı DMÖ nedeni ile IVR tedavisi uygulanan 45 hasta alındı. 22 hastaya unilateral (Grup 1), 23 hastaya bilateral eş zamanlı (Grup 2) IVR tedavisi uygulandı. Tedavi öncesi ve 1.,2., ve 3. aylarda santral foveal kalınlık (SFK) ve en iyi düzeltilmiş görme keskinlikleri (EİDGK) ölçüldü. Gruplar arasında ölçülen SFK, EİDGK ve SFK ve EİDGK değişimleri (Δ) karşılaştırıldı. Sistemik ve lokal komplikasyonlar değerlendirildi. Bulgular: Tedavi öncesi Grup 1'de ortalama SFK 457±157μ, Grup 2'de sağ gözlerde: 462±121 μ, sol gözlerde 442±61 μ idi ve ortalama EİDGK Grup 1'de 0,25±0,15, grup 2 sağ gözlerde: 0,24±0,15, sol gözlerde 0,29±0,16 idi. Ardışık 3 enjeksiyon sonrası, Grup 1 ve Grup 2 sağ ve sol gözler arasında SFK (SFK Grup 1: 243±43 μ, Grup 2 sağ gözler: 243±70 μ, sol gözler: 241±58 μ) ve EİDGK (EİDGK Grup 1: 0,56±0,18, Grup 2 sağ gözler: 0,56±0,25, sol gözler: 0,57±0,25) açısından belirgin fark izlenmedi. ΔSFK ve ΔEİDGK gruplar arasında benzerdi. Unilateral veya bilateral ardışık enjeksiyon yapılan hastaların hiçbirinde sistemik veya lokal komplikasyon izlenmedi. Sonuç: Bilateral veya unilateral enjeksiyonlar sonucu benzer anatomik ve görsel sonuçlar elde edilmiştir. Bilateral enjeksiyonların sağladığı ek bir terapötik etki veya komplikasyon izlenmemiştir.
Anahtar Kelimeler: Diyabetik retinopati; makula ödemi; ranibizumab
Objective: To compare the early anatomic and visual outcomes of bilateral simultaneous and unilateral intravitreal ranibizumab (IVR) injections in diabetic macular edema (DME) Material and Methods: 45 naive DME patients who were applied IVR were included in the study. 22 patients were applied unilateral (Group 1) and 23 patients were applied bilateral simultaneous (Group 2) IVR. Central foveal thickness (CFT) and best corrected visual acuity (BCVA) were evaluated before the treatment and at month 1, 2 and 3. CFT, BCVA and change of CFT and BCVA (Δ) were compared between groups. Systemic and local complications were also determined. Results: Mean CFT was 457±157μ in Group 1. 462±121 μ in the right eyes (RE) and 442±61 μ in the left eyes of Group 2 and mean BCVA was 0.25±0.15 in Group 1, 0.24±0.15 in REs and 0.29±0.16 in LEs of Group 2 before the treatment. There was no significant difference between Group 1 and REs and LEs of Group 2 in terms of CFT (CFT in Group 1: 243±43 μ, REs of Group 2: 243±70 μ and LEs of Group 2: 241±58 μ) and BCVA (BCVA in Group 1: 0.56±0.18, Group 2 REs: 0.56±0.25 and LEs: 0.57±0.25) after 3 consecutive injections. ΔCFT was similar between groups. No systemic or local complications were detected in any of the patients. Conclusion: Anatomic and visual outcomes were similar after unilateral or bilateral injections. No additional therapeutic effect or complication of bilateral injections were detected.
Keywords: Diabetic retinopathy; macular edema; ranibizumab
- Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. [Crossref] [PubMed]
- Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151(2):329-32. [Crossref] [PubMed]
- Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114(5):855-9. [Crossref] [PubMed]
- Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers MB 3rd, Morales-Catón V, QuirozMercado H. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina. 2009;29(1):20-6. [Crossref] [PubMed]
- Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore. 2008;37(7):591-3. [PubMed]
- Acharya NR, Sittivarakul W, Qian Y, Hong KC, Lee SM. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina. 2011;31(9):1871-6. [Crossref] [PubMed]
- Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011; 56(2):95-113. [Crossref] [PubMed]
- Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(5):647-56. [Crossref] [PubMed]
- Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol. 2009;148(1):66-9.e1. [Crossref] [PubMed]
- Abu-Yaghi NE, Shokry AN, Abu-Sbeit RH. Bilateral same-session intravitreal injections of anti-vascular endothelial growth factors. Int J Ophthalmol. 2014;7(6):1017-21. [PubMed] [PMC]
- Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31. [Crossref] [PubMed]
- Mahajan VB, Elkins KA, Russell SR, Boldt HC, Gehrs KM, Weingeist TA, et al. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina. 2011;31(1):315. [Crossref] [PubMed]
- Rotsos T, Symeonidis C, Triantafilloupoulou I, Kanellopoulos S, Kouris A. Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye. Int Ophthalmol. 2014;34(6):1271-4. [Crossref] [PubMed]
- Rouvas A, Liarakos VS, Theodossiadis P, Papathanassiou M, Petrou P, Ladas I, et al. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica. 2009;223(6):383-9. [Crossref] [PubMed]
- Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636-41. [Crossref] [PubMed] [PMC]
- Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54(3):1616-24. [Crossref] [PubMed]
- Zhang Y, Yao Z, Kaila N, Kuebler P, Visich J, Maia M, et al. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology. 2014; 121(11):2237-46. [Crossref] [PubMed]
- Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2): 726-33. [Crossref] [PubMed]
- Lüke J, Nassar K, Grisanti S, Lüke M. Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection. Graefes Arch Clin Exp Ophthalmol. 2013;251(1):371-3. [Crossref] [PubMed]
- Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol. 2010;149(6):939-46.e1. [Crossref] [PubMed]
- Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S. Comparison of the effect of unilateral bevacizumab and ranibizumab on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther. 2013;29(8):728-32. [Crossref] [PubMed]
.: Process List